Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility (< 5 μM), toxicity, and side effects issues of this drug. In this context, the use...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nanoscale Res Lett
Prif Awduron: Benizri, Sebastien, Ferey, Ludivine, Alies, Bruno, Mebarek, Naila, Vacher, Gaelle, Appavoo, Ananda, Staedel, Cathy, Gaudin, Karen, Barthélémy, Philippe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2018
Pynciau:
Nano Express
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5764907/
https://ncbi.nlm.nih.gov/pubmed/29327307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11671-017-2420-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg